AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment

AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient

Ascendis Pharma Secures FDA Approval for YORVIPATH, a Novel Hormone Replacement Therapy for Hypoparathyroidism

Ascendis Pharma, YORVIPATH, FDA approval, hormone replacement therapy, hypoparathyroidism, TransCon PTH, palopegteriparatide

Apellis and Sobi Achieve Significant Breakthrough in Phase 3 Trial for Rare Kidney Disease Treatment

Apellis Pharmaceuticals, Sobi, pegcetacoplan, Phase 3 VALIANT study, C3 glomerulopathy, primary immune complex membranoproliferative glomerulonephritis, proteinuria reduction, kidney disease treatment, FDA approval, European Medicines Agency